Hand-Held Probe for MR Image-Guided Biopsy and Treatment of Prostate Cancer

2001 ◽  
Author(s):  
Charles I. Dumoulin
Keyword(s):  
Prostate Cancer ◽  
Mr Image ◽  
Image Guided ◽  
Guided Biopsy

scholarly journals Multiparametric Magnetic Resonance Imaging and Image-Guided Biopsy to Detect Seminal Vesicle Invasion by Prostate Cancer

2014 ◽  
Vol 28 (11) ◽  
pp. 1283-1289 ◽  
Author(s):  
Dima Raskolnikov ◽  
Arvin K. George ◽  
Soroush Rais-Bahrami ◽  
Baris Turkbey ◽  
Nabeel A. Shakir ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Prostate Cancer ◽  
Magnetic Resonance ◽  
Seminal Vesicle ◽  
Resonance Imaging ◽  
Seminal Vesicle Invasion ◽  
Image Guided ◽  
Multiparametric Magnetic Resonance Imaging ◽  
Guided Biopsy

Multimodality Hyperpolarized C-13 MRS/PET/Multiparametric MR Imaging for Detection and Image-Guided Biopsy of Prostate Cancer: First Experience in a Canine Prostate Cancer Model

2019 ◽  
Vol 21 (5) ◽  
pp. 861-870 ◽  
Author(s):  
Sunitha V. Bachawal ◽  
Jae Mo Park ◽  
Keerthi S. Valluru ◽  
Mathias Dyrberg Loft ◽  
Stephen A. Felt ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Mr Imaging ◽  
Cancer Model ◽  
Image Guided ◽  
Guided Biopsy ◽  
Prostate Cancer Model

MP47-10 MRI USE ALTERS PROSTATE CANCER MANAGEMENT PATTERNS: TREATMENT TRENDS IN THE IMAGE-GUIDED BIOPSY ERA.

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Joseph A. Baiocco ◽  
Abhinav Sidana ◽  
Raju Chelluri ◽  
Kendrick Yim ◽  
Arvin K. George ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Management ◽  
Image Guided ◽  
Guided Biopsy ◽  
Treatment Trends ◽  
Prostate Cancer Management

scholarly journals PD08-07 MOLECULAR PROGRESSION OF GLEASON 6 PROSTATE CANCER: TRACKING OF SPECIFIC CLONES BY IMAGE-GUIDED BIOPSY

2016 ◽  
Vol 195 (4S) ◽  
Author(s):  
Ganesh Palapattu ◽  
Andi Cani ◽  
Daniel Hovelson ◽  
Rohit Mehra ◽  
Jeffery Montgomery ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Image Guided ◽  
Guided Biopsy

scholarly journals Percutaneous image-guided biopsy of prostate cancer metastases yields samples suitable for genomics and personalised oncology

2013 ◽  
Vol 31 (2) ◽  
pp. 159-167 ◽  
Author(s):  
Matthew K. H. Hong ◽  
Nikhil Sapre ◽  
Pramit M. Phal ◽  
Geoff Macintyre ◽  
Xiaowen Chin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Image Guided ◽  
Guided Biopsy ◽  
Cancer Metastases

scholarly journals Re-evaluating the diagnostic efficacy of PSA as a referral test to detect clinically significant prostate cancer in contemporary MRI-based image-guided biopsy pathways

2021 ◽  
pp. 205141582110590
Author(s):  
Artitaya Lophatananon ◽  
Alexander Light ◽  
Nicholas Burns-Cox ◽  
Angus Maccormick ◽  
Joseph John ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Predictive Value ◽  
Histological Grade ◽  
Specific Antigen ◽  
Added Value ◽  
Reference Ranges ◽  
Level Of Evidence ◽  
Image Guided ◽  
Guided Biopsy ◽  
Clinically Significant

Introduction: Modern image-guided biopsy pathways at diagnostic centres have greatly refined the investigations of men referred with suspected prostate cancer. However, the referral criteria from primary care are still based on historical prostate-specific antigen (PSA) cut-offs and age-referenced thresholds. Here, we tested whether better contemporary pathways and biopsy methods had improved the predictive utility value of PSA referral thresholds. Methods: PSA referral thresholds, age-referenced ranges and PSA density (PSAd) were assessed for positive predictive value (PPV) in detection of clinically significant prostate cancer (csPCa – histological ⩾ Grade Group 2). Data were analysed from men referred to three diagnostics centres who used multi-parametric magnetic resonance imaging (mpMRI)-guided prostate biopsies for disease characterisation. Findings were validated in a separate multicentre cohort. Results: Data from 2767 men were included in this study. The median age, PSA and PSAd were 66.4 years, 7.3 ng/mL and 0.1 ng/mL2, respectively. Biopsy detected csPCa was found in 38.7%. The overall area under the curve (AUC) for PSA was 0.68 which is similar to historical performance. A PSA threshold of ⩾ 3 ng/mL had a PPV of 40.3%, but this was age dependent (PPV: 24.8%, 32.7% and 56.8% in men 50–59 years, 60–69 years and ⩾ 70 years, respectively). Different PSA cut-offs and age-reference ranges failed to demonstrate better performance. PSAd demonstrated improved AUC (0.78 vs 0.68, p < 0.0001) and improved PPV compared to PSA. A PSAd of ⩾ 0.10 had a PPV of 48.2% and similar negative predictive value (NPV) to PSA ⩾ 3 ng/mL and out-performed PSA age-reference ranges. This improved performance was recapitulated in a separate multi-centre cohort ( n = 541). Conclusion: The introduction of MRI-based image-guided biopsy pathways does not appear to have altered PSA diagnostic test characteristics to positively detect csPCa. We find no added value to PSA age-referenced ranges, while PSAd offers better PPV and the potential for a single clinically useful threshold (⩾0.10) for all age groups. Level of evidence: IV

Sign in / Sign up

Export Citation Format

Share Document